Cited by 296Renin-Angiotensin System StudiesCoagulation, Bradykinin, Polyphosphates, and AngioedemaEicosanoids and Hypertension Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis

Open access
Iwai, Masaru, Horiuchi, Masatsugu·2009·Hypertension Research

Abstract

Recent studies have established a new regulatory axis in the renin-angiotensin system (RAS). In this axis, angiotensin (Ang)-(1-7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1-7) shows actions different from those of AT(1) receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin-NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT(1) receptor axis. The signaling pathway of the ACE2-Ang-(1-7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1-7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1-7). However, this second axis through ACE2 and Ang-(1-7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/hr.2009.74

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 1

  1. Santos RA, Ferreira AJ, E Silva AC . Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519–527. · DOI

Cited by

Sorted by citations

Items 101–200 of 296

Metadata

Authors
Iwai, M., & Horiuchi, M.
Affiliations
Ehime University (JP)
Corresponding author
Horiuchi, Masatsugu
Venue
Hypertension Research
Published
2009-05-22
Volume
32
Issue
7
Pages
533-536
ISSN
  • 0916-9636 (ISSN-L)
  • 1348-4214
OpenAlex
W2067142583
Cited by
296
References
37
Citations by year
2026: 9 · 2025: 9 · 2024: 11 · 2023: 20 · 2022: 21 · 2021: 29 · 2020: 29 · 2019: 12 · 2018: 14 · 2017: 10 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 19 · 2012: 23
FWCI
2.51
Type
journal article
Language
en
Open access
Locations
  • Hypertension Research (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
renin-angiotensin system, angiotensin-(1-7), angiotensin-converting enzyme 2, Mas receptor, angiotensin II type 1 receptor, angiotensin II, vasodilation, sodium excretion, Akt phosphorylation, protein kinase C, MAP kinase inhibition, cardiovascular disease treatment
MeSH terms
Angiotensin-Converting Enzyme 2, Proto-Oncogene Mas, Angiotensin I, Animals, Humans, Peptidyl-Dipeptidase A, Peptide Fragments, Proto-Oncogene Proteins, Renin-Angiotensin System, Signal Transduction, Receptors, G-Protein-Coupled, Receptor, Angiotensin, Type 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review